Dalton Transactions · 2019 · 40 citations · 36 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DeliveryProdrug DesignAnticancer Prodrug DesignAnticancer ActivityCellular AccumulationCellular Drug AccumulationChemotherapeutic Prodrug DesignLipophilic ProdrugsNanocarrier-based ProdrugsPlatinum CompoundsPlatinum-based Agents
Lipophilic platinum(iv) complexes were synthesised of the type [Pt(HL)(AL)(OH)(R)]2+ and [Pt(HL)(AL)(R)2]2+ (HL = 5,6-dimethyl-1,10-phenanthroline or 1,10-phenanthroline; AL = 1S,2S-diaminocyclohexane and R = increasingly lipophilic carboxylate axial ligands (C10-18)) from hydrophilic platinum(ii) precursors that exhibit exceptional anticancer activity. The increased overall lipophilicity of the complexes suggested the formation of spontaneously self-assembled structures in an aqueous environment. The anti-proliferative properties were assessed against one non-cancerous and a panel of cancerous cell lines. Nanomolar levels of activity were observed against several cell lines, with the lowest GI50 of 3.4 nm against the Du145 prostate cancer cell line and over 1100-fold greater activity than cisplatin against HT29 colon carcinoma. RP-HPLC was utilised to establish the relative lipophilicities of each complex. While there seemed to be an increase in cellular accumulation for the lipophilic derivatives in some instances, ICP-MS studies showed no clear correlation between increasing lipophilicity, cellular accumulation and cytotoxicity.
36
The status of platinum anticancer drugs in the clinic and in clinical trials
Nial Wheate, Shonagh Walker, Gemma E. Craig et al. · Dalton Transactions · 2010 · 1.6K citations
Medicine, Oncology, Pharmacology +15